C07D 217/22
Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems: with hetero atoms
Official title: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D217/22 (Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems: with hetero atoms) appears on 1,721 US grants and 1,554 published applications in this corpus.
Search patents in C07D- Granted patents
- 1,721
- Published applications
- 1,554
- Assignees
- 805
- Inventors
- 5,421
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 19 | 0 |
| 1977 | 23 | 0 |
| 1978 | 33 | 0 |
| 1979 | 12 | 0 |
| 1980 | 9 | 0 |
| 1981 | 18 | 0 |
| 1982 | 14 | 0 |
| 1983 | 11 | 0 |
| 1984 | 10 | 0 |
| 1985 | 18 | 0 |
| 1986 | 20 | 0 |
| 1987 | 22 | 0 |
| 1988 | 12 | 0 |
| 1989 | 17 | 0 |
| 1990 | 14 | 0 |
| 1991 | 10 | 0 |
| 1992 | 15 | 0 |
| 1993 | 25 | 0 |
| 1994 | 18 | 0 |
| 1995 | 28 | 0 |
| 1996 | 52 | 0 |
| 1997 | 47 | 0 |
| 1998 | 38 | 0 |
| 1999 | 44 | 0 |
| 2000 | 37 | 0 |
| 2001 | 40 | 9 |
| 2002 | 58 | 61 |
| 2003 | 53 | 66 |
| 2004 | 44 | 93 |
| 2005 | 26 | 63 |
| 2006 | 39 | 56 |
| 2007 | 44 | 73 |
| 2008 | 50 | 64 |
| 2009 | 27 | 58 |
| 2010 | 42 | 88 |
| 2011 | 53 | 53 |
| 2012 | 49 | 61 |
| 2013 | 55 | 64 |
| 2014 | 65 | 83 |
| 2015 | 77 | 89 |
| 2016 | 51 | 65 |
| 2017 | 59 | 57 |
| 2018 | 46 | 53 |
| 2019 | 39 | 48 |
| 2020 | 44 | 59 |
| 2021 | 47 | 54 |
| 2022 | 35 | 52 |
| 2023 | 36 | 68 |
| 2024 | 22 | 45 |
| 2025 | 27 | 41 |
| 2026 | 27 | 31 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Process for the preparation of bromodomain inhibitor8 Sep 2026US 12,729,183 B2Celgene Quanticel Research, Inc.
- Fused ring compound and application thereof28 Jul 2026US 12,692,235 B2Wuhan Ll Science and Technology Development Co., Ltd.
- 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)23 Jun 2026US 12,662,471 B2Vertex Pharmaceuticals Incorporated
- HDAC6 inhibitors and uses thereof16 Jun 2026US 12,655,106 B2Eikonizo Therapeutics, Inc.
- MRGPRX2 antagonist for the treatment of pseudo allergic reactions2 Jun 2026US 12,642,795 B2The University of Hong Kong
- Bicyclic compounds8 Oct 2026US 2026/0308114 A1Vivace Therapeutics, Inc.
- Usp30 inhibitors and uses thereof1 Oct 2026US 2026/0297026 A1Vincere Biosciences, Inc.
- Modulators of sortilin activity24 Sep 2026US 2026/0285802 A1
- A method for synthesizing aryl ethers ortho-substituted to the nitrogen atom of n-heterocycles3 Sep 2026US 2026/0257997 A1Xinjiang University
- Process for the preparation of (6s,9r)-3-oxo-3,5,6,7,8,9-hexahydro-2h-6,9-epiminocyclohepta[c]pyridazine-10-carboxamide derivatives3 Sep 2026US 2026/0258043 A1Pathios Therapeutics Limited
Most cited
By later US patents
- Heterocyclic compounds useful as inhibitors of tyrosine kinases202US 6,506,769 B2Boehringer Ingelheim Pharmaceuticals, Inc. · 2003
- Heterocyclic compounds useful as inhibitors of tyrosine kinases190US 6,770,639 B2Boehringer Ingelheim Pharmaceuticals, Inc. · 2004
- Retroviral protease inhibiting compounds159US 5,142,056 AAbbott Laboratories · 1992
- Benzamides and related inhibitors of factor Xa155US 7,285,565 B2Millennium Pharmaceuticals, Inc. · 2007
- Isoquinolinone derivatives and their use as therapeutic agents148US 7,265,131 B2Exelixis, Inc. · 2007